Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label study to investigate the safety and pharmacokinetics of multiple ascending doses of antisense oligonucleotide STK-001 in children and adolescents with Dravet syndrome

Next Previous
Trial Profile

An open-label study to investigate the safety and pharmacokinetics of multiple ascending doses of antisense oligonucleotide STK-001 in children and adolescents with Dravet syndrome

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zorevunersen (Primary)
  • Indications Dravet syndrome
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms ADMIRAL; STK-001-DS-102 (ADMIRAL)
  • Sponsors Stoke Therapeutics

Most Recent Events

  • 05 Dec 2025 According to the Stoke Therapeutics media release, data from this trial were presented at the 2025 American Epilepsy Society (AES) Annual Meeting in Atlanta, Georgia.
  • 01 Dec 2025 According to the Stoke Therapeutics media release, data from the trial will be presented at the 2025 American Epilepsy Society (AES) Annual Meeting, taking place December 5-9 in Atlanta, Georgia.
  • 02 Sep 2025 According to a Biogen media release, data from Phase 1/2a and open-label extension (OLE) studies of zorevunersen support the EMPEROR Phase 3 study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top